We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0HIY market cap is 297.38M. The company's latest EPS is USD -14.7756 and P/E is -0.62.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 20.34M | 63.57M | 8.57M | 128.94M |
| Operating Income | -309.05M | -340.46M | -280.51M | -276.01M | -83.44M |
| Net Income | -306.62M | -340.14M | -230M | -276.13M | -85.4M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 588.12M | 468.13M | 376.42M | 165.5M | 109.1M |
| Total Liabilities | 125.78M | 188.51M | 249.78M | 264.74M | 206.38M |
| Total Equity | 462.34M | 279.61M | 126.64M | -99.23M | -97.28M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -180.76M | -220.52M | -270.43M | -192.98M | -68.72M |
| Investing | -120.73M | 22.26M | 202.96M | 123.87M | 8.62M |
| Financing | 427.57M | 103.94M | 53.08M | 2.01M | 59.28M |
| Market Cap | 297.38M |
| Price to Earnings Ratio | -0.62 |
| Price to Sales Ratio | 0.41 |
| Price to Cash Ratio | 2.12 |
| Price to Book Ratio | -0.54 |
| Dividend Yield | - |
| Shares Outstanding | 5.78M |
| Average Volume (1 week) | 358 |
| Average Volume (1 Month) | 181 |
| 52 Week Change | -96.00% |
| 52 Week High | 1,286.25 |
| 52 Week Low | 51.45 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Atara Biotherapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.atarabio.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
